Pablo Tebas, MD

faculty photo
Professor of Medicine (Infectious Diseases) at the Hospital of the University of Pennsylvania
Attending Physician, Hospital of the University of Pennsylvania
Director & Principal Investigator, AIDS Clinical Trial Unit (ACTU) research site, University of Pennsylvania
Investigator of the Vaccine Trials Network, University of Pennsylvania
Department: Medicine

Contact information
Academic Address: 502 Johnson Pavilion
Clinical Office: 4 Perelman Center for Advanced Medicine, 3600 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-8092
Fax: 215-349-8011
Universidad Autónoma de Madrid, Spain, 1985.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

My research interests center around the study of the complications of HIV and its treatment, and currently in the evaluation of strategies for the cure of HIV infection.
I am the director and the PI of the AIDS clinical trial unit of the University of Pennsylvania.
I am one of the founding members of the HIV Reservoirs and Viral Eradication (Cure) Transformative Science Group (TSG) of the AIDS clinical trial group. In addition to my ACTG work, I am involved (as PI of the clinical project) in several early phase trials of new compounds developed in conjunction with the NIH in several IPCP grants, including a Phase I study evaluating the antiviral activity of aprepitant (an NK-1R antagonist that down-regulates the expression of CCR5), a phase I study evaluating the immunogenicity of a therapeutic DNA vaccine administered by intramuscular electroporation in collaboration with David Weiner and several gene therapy studies evaluating the therapeutic use of lentiviral vectors in the management of HIV infection (including the use of VIRxSYS 496 –antisense approach-, the first in humans Sangamo’s zinc finger nuclease for CCR5 edition, in collaboration with Dr. Carl June.

Description of Clinical Expertise

My clinical interest focus on the treatment of HIV infection and associated infections like hepatitis C. I have also a particular interest in the clinical manifestations and treatment of atypical mycobacterial infections. I also attend every year in the general infectious disease service of the hospital of University of Pennsylvania

Selected Publications

Parzych, E. M., Du, J., Ali, A. R., Schultheis, K., Frase, D., Smith, T. R. F., Cui, J., Chokkalingam, N., Tursi, N. J., Andrade, V. M., Warner, B. M., Gary, E. N., Li, Y., Choi, J., Eisenhauer, J., Maricic, I., Kulkarni, A., Chu, J. D., Villafana, G., Rosenthal, K., Ren, K., Francica, J. R., Wootton, S. K., Tebas, P., Kobasa, D., Broderick, K. E., Boyer, J. D., Esser, M. T., Pallesen, J., Kulp, D. W., Patel, A., Weiner, D. B.: DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2. Nat Commun 13(1): 5886, October 2022.

Neergaard, R., Jones, N. L., Roebuck, C., Rendle, K. A., Barbati, Z., Peterson, B., Tebas, P., Mounzer, K., Metzger, D., Montaner, L. J., Dube, K., Barg, F. K.: "I Know That I Was a Part of Making a Difference": Participant Motivations for Joining a Cure-Directed HIV Trial with an Analytical Treatment Interruption. AIDS Res Hum Retroviruses September 2022.

Schnittman, S. R., Lu, M. T., Mayrhofer, T., Burdo, T. H., Fitch, K. V., McCallum, S., Fulda, E. S., Zanni, M. V., Borek, F., Malvestutto, C., Fichtenbaum, C. J., Aberg, J. A., Bloomfield, G. S., Overton, E. T., Currier, J., Tebas, P., Sha, B. E., Ribaudo, H. J., Flynn, J. M., Douglas, P. S., Erlandson, K. M., Grinspoon, S. K.: Cytomegalovirus IgG Titer and Coronary Artery Disease in People with HIV. Clin Infect Dis August 2022.

Dube, K., Agarwal, H., Carter, W. B., Dee, L., Taylor, J., Roebuck, C., Peterson, B., Patel, H., Ndukwe, S., Lynn, K. M., Lalley-Chareczko, L., Hiserodt, E., Kim, S., Rosenbloom, D., Evans, B. R., Anderson, M., Hazuda, D. J., Bateman, K., Howell, B. J., Azzoni, L., Mounzer, K., Tebas, P., Montaner, L. J.: Participant experiences using novel home-based blood collection device for viral load testing in the HIV cure trials with analytical treatment interruptions. HIV Res Clin Pract 23(1): 76-90, August 2022.

Fintzi, J., Bonnett, T., Tebas, P., Marconi, V. C., Levine, C. B., El Sahly, H. M., McLellan, S. L. F., Benson, C. A., Rostad, C. A., Ganesan, A., Huprikar, N., Frank, M. G., Mularski, R. A., Atmar, R. L., Park, P. K., Short, W. R., Beigel, J. H., Mehta, A. K., Sweeney, D. A.: Unraveling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2. Open Forum Infect Dis 9(7): ofac219, July 2022.

Daniell, H., Nair, S. K., Guan, H., Guo, Y., Kulchar, R. J., Torres, M. D. T., Shahed-Al-Mahmud, M., Wakade, G., Liu, Y. M., Marques, A. D., Graham-Wooten, J., Zhou, W., Wang, P., Molugu, S. K., de Araujo, W. R., de la Fuente-Nunez, C., Ma, C., Short, W. R., Tebas, P., Margulies, K. B., Bushman, F. D., Mante, F. K., Ricciardi, R. P., Collman, R. G., Wolff, M. S.: Debulking different Corona (SARS-CoV-2 delta, omicron, OC43) and Influenza (H1N1, H3N2) virus strains by plant viral trap proteins in chewing gums to decrease infection and transmission. Biomaterials 288: 121671, July 2022.

Fintzi, J., Bonnett, T., Sweeney, D. A., Huprikar, N. A., Ganesan, A., Frank, M. G., McLellan, S. L. F., Dodd, L. E., Tebas, P., Mehta, A. K.: Deconstructing the Treatment Effect of Remdesivir in the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1: Implications for Critical Care Resource Utilization. Clin Infect Dis 74(12): 2209-2217, July 2022.

Pedersen, S. F., Collora, J. A., Kim, R. N., Yang, K., Razmi, A., Catalano, A. A., Yeh, Y. J., Mounzer, K., Tebas, P., Montaner, L. J., Ho, Y. C.: Inhibition of a Chromatin and Transcription Modulator, SLTM, Increases HIV-1 Reactivation Identified by a CRISPR Inhibition Screen. J Virol 96(13): e0057722, June 2022.

Blumberg, E. A., Noll, J. H., Tebas, P., Fraietta, J. A., Frank, I., Marshall, A., Chew, A., Veloso, E. A., Carulli, A., Rogal, W., Gaymon, A. L., Schmidt, A. H., Barnette, T., Jurek, R., Martins, R., Hudson, B. M., Chavda, K., Bailey, C. M., Church, S. E., Noorchashm, H., Hwang, W. T., June, C. H., Hexner, E. O.: A phase I trial of cyclosporine for hospitalized patients with COVID-19. JCI Insight 7(11), May 2022.

Dube, K., Kanazawa, J., Roebuck, C., Johnson, S., Carter, W. B., Dee, L., Peterson, B., Lynn, K. M., Lalley-Chareczko, L., Hiserodt, E., Kim, S., Rosenbloom, D., Evans, B. R., Anderson, M., Hazuda, D. J., Shipley, L., Bateman, K., Howell, B. J., Mounzer, K., Tebas, P., Montaner, L. J.: "We are looking at the future right now": community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States. HIV Res Clin Pract Page: 1-16, March 2022.

back to top
Last updated: 10/17/2022
The Trustees of the University of Pennsylvania